	US 12,291,558 B2
	CD1D-restricted NKT cells as a platform for off-the-shelf cancer immunotherapy
Leonid S. Metelitsa, Sugar Land, TX (US); Jingling Jin, Houston, TX (US); and Bin Liu, Richmond, TX (US)
Assigned to Baylor College of Medicine, Houston, TX (US)
Appl. No. 16/637,986
Filed by Baylor College of Medicine, Houston, TX (US)
PCT Filed Aug. 10, 2018, PCT No. PCT/US2018/046306 § 371(c)(1), (2) Date Feb. 10, 2020, PCT Pub. No. WO2019/033023, PCT Pub. Date Feb. 14, 2019.
Claims priority of application No. 17185992 (EP), filed on Aug. 11, 2017.
Prior Publication US 2020/0216810 A1, Jul. 9, 2020
Int. Cl. C12N 15/11 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01)

CPC C07K 14/7051 (2013.01) [A61K 39/4613 (2023.05); A61K 39/4631 (2023.05); A61K 39/464411 (2023.05); A61K 39/464412 (2023.05); A61K 39/464471 (2023.05); C07K 14/70521 (2013.01); C07K 14/70596 (2013.01); C12N 5/0646 (2013.01); C12N 15/11 (2013.01); C12N 15/86 (2013.01); A61K 2239/26 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C12N 2310/531 (2013.01); C12N 2510/00 (2013.01); C12N 2740/10043 (2013.01)]

20 Claims

1. A modified isolated CD1d-restricted human natural killer T (NKT) cell or a plurality of cells thereof, having, when compared to an unmodified CD1d-restricted human NKT cell, reduced but detectable expression of:

(a) endogenous beta-2-microglobulin (B2M) and

(b) endogenous MHC class II-associated invariant chain (Ii); and

wherein the modified cell or cells comprise synthetic DNA or RNA that targets a gene encoding B2M or a gene encoding Ii.